{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T08:13:25Z","timestamp":1783930405364,"version":"3.55.0"},"reference-count":53,"publisher":"Informa UK Limited","issue":"14","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Astellas Pharma Inc"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncology"],"published-print":{"date-parts":[[2026,6,9]]},"DOI":"10.1080\/14796694.2026.2677774","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T08:02:09Z","timestamp":1783584129000},"page":"1601-1612","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Enzalutamide in biochemically recurrent prostate cancer: clinical implications from EMBARK for real-world practice"],"prefix":"10.1080","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8104-6419","authenticated-orcid":false,"given":"Stephen J.","family":"Freedland","sequence":"first","affiliation":[{"name":"Cedars\u2011Sinai Medical Center","place":["Los Angeles, USA"]},{"name":"Durham VA Medical Center","place":["Durham, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5767-0548","authenticated-orcid":false,"given":"Neal D.","family":"Shore","sequence":"additional","affiliation":[{"name":"START Carolinas\/Carolina Urologic Research Center","place":["Myrtle Beach, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2025.2478786"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2025.2479331"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2026.2676559"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2025.2475730"},{"key":"e_1_3_6_7_1","unstructured":"U.S. Food & Drug Administration. FDA approves enzalutamide for non-metastatic castration-sensitive prostate cancer with biochemical recurrence. 2023 [cited 2026 May 11]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-enzalutamide-non-metastatic-castration-sensitive-prostate-cancer-biochemical-recurrence"},{"key":"e_1_3_6_8_1","unstructured":"Astellas Pharma Inc. Patient Information: XTANDI\u00ae (enzalutamide). 2023 [cited 2026 May 11]. Available from: https:\/\/www.astellas.us\/docs\/us\/12A005-ENZ-Patient%20Package%20Insert-WPI.pdf?v=1"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003361.09"},{"key":"e_1_3_6_10_1","volume-title":"Presented at: European Society for Medical Oncology","author":"Freedland SJ, Shore ND, de Almeida Luz M","year":"2025","unstructured":"Freedland SJ, Shore ND, de Almeida Luz M. et al. EMBARK: overall survival with enzalutamide in biochemically recurrent prostate cancer. Presented at: European Society for Medical Oncology; Berlin, Germany; 2025 Oct 17\u201321."},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.2716"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303974"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2510310"},{"key":"e_1_3_6_14_1","unstructured":"European Medicines Agency. Xtandi. 2025 [cited 2026 Feb 5]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xtandi"},{"key":"e_1_3_6_15_1","unstructured":"Pfizer. XTANDI\u00ae (enzalutamide) approved by U.S. FDA for the treatment of metastatic castration-sensitive prostate cancer. 2019 [cited 2026 May 11]. Available from: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/xtandi_enzalutamide_approved_by_u_s_fda_for_the_treatment_of_metastatic_castration_sensitive_prostate_cancer"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.0572"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000004879"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000004890"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1201546"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103429"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.03.027"},{"key":"e_1_3_6_22_1","unstructured":"U.S. Food & Drug Administration. Full prescribing information: XTANDI\u00ae (enzalutamide) for oral use. 2025 [cited 2026 Feb 5]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/203415s025 213674s015lbl.pdf"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjmsu.2011.08.006"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.52971"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00730-7"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3455-6"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.10.012"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810095"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.4800"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00799"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00193"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.5079"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.3657"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.5005"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02437-5"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800536"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.4_suppl.313"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2025.02.006"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2300251"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2025.11.015"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1405095"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1207506"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00518-5"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.9285"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60172-9"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102209"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.119.313046"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2020.08.003"},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.22.4.232"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.1641"},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euros.2025.01.001"},{"key":"e_1_3_6_52_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0136094"},{"key":"e_1_3_6_53_1","doi-asserted-by":"publisher","DOI":"10.3747\/co.19.993"},{"key":"e_1_3_6_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2012.01.036"},{"key":"e_1_3_6_55_1","volume-title":"Presented at: 2024 Advanced Prostate Cancer Consensus Conference","author":"Horvath L","year":"2024","unstructured":"Horvath L. Gynecomastia \u2013 how to assess and treat? Presented at: 2024 Advanced Prostate Cancer Consensus Conference; Lugano, Switzerland; 2024 Apr 25\u201327."}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2026.2677774","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14796694.2026.2677774","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2026.2677774","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T08:02:16Z","timestamp":1783929736000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14796694.2026.2677774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":53,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2026,6,9]]}},"alternative-id":["10.1080\/14796694.2026.2677774"],"URL":"https:\/\/doi.org\/10.1080\/14796694.2026.2677774","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-08-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}